7 minutes | Jan 4, 2021

Baricitinib plus Remdesivir for Hospitalized Adults with COVID-19 (ACTT-2)

A randomized, multicenter, adaptive, double-blind, placebo-controlled trial to evaluate whether the combination of baricitinib plus remdesivir was superior to remdesivir alone.
Play
Like
Play Next
Mark
Played
Share